Search clinical trials for: Monoclonal antibodies (mAbs)

Total 5637 results

City of Hope Medical Center
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC

Locally Advanced Skin Squamous Cell Carcinoma | Unresectable Skin Squamous Cell Carcinoma | Resectable Skin Squamous Cell Carcinoma

United States
Peking University Cancer Hospital & Institute

Not yet recruiting

Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis

Melanoma Stage IV
Peking University Cancer Hospital & Institute

Not yet recruiting

Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis

Melanoma Stage IV
National Cancer Institute (NCI)

Recruiting

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage IV Hypopharyngeal... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Advanced Extrapulmonary Neuroendocrine Carcinoma | Metastatic Extrapulmonary Neuroendocrine Carcinoma | Recurrent Extrapulmonary Neuroendocrine Carcinoma | Unresectable Extrapulmonary Neuroendocrine Carcinoma

United States
Mehrdad Abedi, MD
National Cancer Institute (NCI)

Recruiting

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
Akesobio Australia Pty Ltd

Recruiting

Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Australia, New Zealand
IRCCS National Neurological Institute "C. Mondino...

Not yet recruiting

Psychological and Biological Markers of Refractory Migraine

Migraine

Italy
Fundació Institut de Recerca de l'Hospital de la...

Recruiting

Pharmacogenetic Studies on Anti-IL-6 Receptor Monoclonal Antibodies on the Treatment of Rheumatic Diseases

Rheumatoid Arthritis | Giant Cell Arteritis | Idiopathic Juvenile Arthritis | Still Disease

Spain
Patrick Robinson

Recruiting

Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19

Covid19 | COVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Acute Bronchitis

United States
University of Oxford

Recruiting

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PLATCOV)

COVID-19

Lao People's Democratic Republic, Thailand, Brazil, Pakistan
M.D. Anderson Cancer Center

Recruiting

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Chondrosarcoma | Advanced Malignant Solid Neoplasm | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma

Chordoma | Metastatic Chordoma | Unresectable Chordoma

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma

United States
The First Affiliated Hospital of Soochow University

Recruiting

Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy (SEHC)

EBV Infection

China
M.D. Anderson Cancer Center

Recruiting

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Recurrent Glioblastoma | Recurrent Gliosarcoma

United States
M.D. Anderson Cancer Center

Recruiting

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Lymphoblastic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia | Refractory Lymphoblastic Lymphoma

United States
M.D. Anderson Cancer Center

Recruiting

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Richter Syndrome | Refractory Mantle Cell Lymphoma | Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory... and other conditions

United States
Pregistry

Recruiting

COVID-19 International Drug Pregnancy Registry (COVID-PR)

Covid19

United States
Shanghai Zhongshan Hospital

Not yet recruiting

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Non-Small Cell Lung Cancer

China
Shanghai Henlius Biotech

Recruiting

Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

Age Related Macular Degeneration

China
National Cancer Institute (NCI)

Recruiting

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Peritoneal Malignant Mesothelioma

United States
Shanghai Changzheng Hospital
Zhejiang Provincial Hospital of TCM; The First People's Hospital of Kunshan; Traditional... and other collaborators

Not yet recruiting

TNFα Monoclonal Antibody for Acute Spinal Cord Injury

Spinal Cord Injuries

China
Boris Juelg, MD PhD
National Institute of Allergy and Infectious Diseases (NIAID); The University... and other collaborators

Recruiting

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

Acquired Immunodeficiency Syndrome | Sexually Transmitted Diseases, Viral | Retroviridae Infections | HIV | Immunologic Deficiency Syndrome, Acquired

United States
National Cancer Institute (NCI)

Recruiting

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Sporadic Papillary Renal Cell Carcinoma

United States
Shanghai Chest Hospital

Recruiting

Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
M.D. Anderson Cancer Center

Recruiting

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Diffuse Large B-Cell Lymphoma

United States
Peking Union Medical College Hospital

Recruiting

An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients

Psoriatic Arthritis

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

Treatment of Advanced and Metastatic Solid Tumors With MIL97

Advanced or Metastatic Solid Tumor

China
Sun Yat-sen University

Recruiting

Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
M.D. Anderson Cancer Center

Recruiting

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Borderline Resectable Pancreatic Adenocarcinoma | Stage IA Pancreatic Cancer AJCC v8 | Stage IB Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Resectable Pancreatic Adenocarcinoma

United States
Blokhin's Russian Cancer Research Center

Recruiting

Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy

Melanoma

Russian Federation
Novartis Pharmaceuticals

Recruiting

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Multiple Sclerosis (MS)

United States, Belgium, Spain, Taiwan, Italy, Germany, Canada, Estonia, Mexico, Croatia, Slovakia, Turkey, India, Argentina, France, Israel, Australia, Austria, Serbia, Brazil, Guatemala, Latvia, Poland, Portugal, Russian Federation, Romania and more
Fundacion para la Investigacion Biomedica del Hospital...

Recruiting

Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy

Lung Cancer

Spain
Dwight Owen

Recruiting

All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Dwight Owen
Genentech, Inc.

Recruiting

Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Metastatic Lung Small Cell Carcinoma | Recurrent Lung Small Cell Carcinoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma and other conditions

United States
Fondazione Italiana Linfomi - ETS
Janssen-Cilag S.p.A.

Recruiting

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. (FIL_DALYA)

Plasmablastic Lymphoma

Italy
Beijing Friendship Hospital
Xuanwu Hospital, Beijing; Beijing Chao Yang Hospital; Tianjin Medical University... and other collaborators

Recruiting

Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.

Colorectal Neoplasms

China
M.D. Anderson Cancer Center

Recruiting

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8 and other conditions

United States
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC (BASKETⅡ)

Colorectal Cancer | Immunotherapy

China
M.D. Anderson Cancer Center

Recruiting

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Stage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIC Lung Cancer AJCC v8 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7

United States
University of Washington
Genzyme, a Sanofi Company

Recruiting

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
Beijing Dongfang Biotech Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting

JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety

NSCLC
OHSU Knight Cancer Institute
AbbVie; Oregon Health and Science University

Recruiting

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

B Acute Lymphoblastic Leukemia | Recurrent B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Mixed Phenotype Acute Leukemia

United States
Lawson Health Research Institute
Mount Sinai Hospital, Canada

Recruiting

Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis

Chronic Rhinosinusitis With Nasal Polyps | Olfactory Disorder

Canada
Asylia Diagnostics BV

Recruiting

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

Melanoma | Lung Cancer

Belgium
Great Ormond Street Hospital for Children NHS Foundation...

Recruiting

90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (RITII)

Leukemia

United Kingdom
Yazeed Sawalha

Recruiting

Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

United States
Fudan University

Recruiting

PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP

Cancer of Unknown Primary

China

Search clinical trials for: Monoclonal antibodies (mAbs)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations